Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

22.12.2021 | short review

New targeted therapies in kidney cancer

verfasst von: Karl Mayrhofer, MD, Dora Niedersüß-Beke, MD, MBA

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Summary

New agents and combinations continue to change the clinical practice of treating patients with renal cell carcinoma. In this review we want to highlight the most recent therapeutic developments and also give an overview of the current standard of care in advanced disease. Studies investigating lenvatinib plus pembrolizumab, belzutifan and cabozantinib are discussed.
Vorheriger Artikel Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer
Nächster Artikel Tracking mutation and drug-driven alterations of oncokinase conformations
Literatur
1.
Motzer R, Alekseev B, Rha S‑Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300.CrossRef
2.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.CrossRef
3.
Bauer TM, Choueiri TK, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273.CrossRef
4.
Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(15_suppl):4555.CrossRef
5.
Choueiri TK, Bauer TM, McDermott DF, Arrowsmith E, Roy A, Perini RF, et al. Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2021;39(6_suppl):272.CrossRef
6.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–88.CrossRef
7.
Song SH, Jeong IG, You D, Hong JH, Hong BS, Song C, et al. VEGF/VEGFR2 OR PDGF-β/PDGFR‑β expression in non-metastatic, renal cell carcinoma: a prospective study WiTH 1,091 consecutive cases. Int J Clin Exp Pathol. 2014;7:7681–9.
8.
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–45.CrossRef
9.
Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703.CrossRef
10.
11.
Lee C‑H, Voss MH, Carlo MI, Chen Y‑B, Reznik E, Knezevic A, et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4509.CrossRef
12.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41.CrossRef
13.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27.CrossRef
14.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90.CrossRef
Metadaten
Titel
New targeted therapies in kidney cancer
verfasst von
Karl Mayrhofer, MD
Dora Niedersüß-Beke, MD, MBA
Publikationsdatum
22.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00782-6

Weitere Artikel der Ausgabe 2/2022

COVID-19: New disease mechanism is simultaneously a therapeutic target

  • editorial

Hemophagocytic lymphohistocytosis in a COVID-19 patient in the acute phase: case report

  • case report

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

  • Open Access
  • short review

ESMO 2021

  • editorial

Antibody–drug conjugates—the magic bullet?

  • Open Access
  • short review

Immunotherapy pitfall: sarcoid-like reaction mimicking disease progression in advanced melanoma treated with nivolumab

  • case report